Typhim Vi®

BIOLOGICAL2 trials

Sponsors

International Vaccine Institute, EuBiologics Co.,Ltd

Conditions

TyphoidTyphoid Fever

Phase 1

Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

CompletedNCT02645032

International Vaccine InstituteTyphoid

Start: 2016-05-19End: 2017-02-09Updated: 2020-04-28

Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

CompletedNCT03956524

EuBiologics Co.,LtdTyphoid Fever

Start: 2019-03-16End: 2019-08-31Updated: 2019-12-09

Related Papers

An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.

2021-04-107 citations

Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.

2018-06-0136 citations